Amneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $535 million versus the consensus estimate of $523.25 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2021 EPS of $0.70-$0.85, versus the consensus of $0.82. Amneal Pharmaceuticals sees FY2021 revenue of $2.1-2.2 million, versus the consensus of $2.12 million.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.